MilliporeSigma Invests €35 Million to Strengthen Biosafety Testing in Scotland

Under the €35 million (US$37 million) investment, MilliporeSigma will expand its sites in Glasgow and Stirling, Scotland, to increase biosafety testing for drug development and commercialization.